Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Li, Songtao ^a   Meng, Fanyu ^a   Liao, Xilu ^a   Wang, Yemei ^a   Sun, Zongxiang ^a   Guo, Fuchuan ^a   Li, Xiaoxia ^a   Meng, Man ^a   Li, Ying ^a   Sun, Changhao ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; URSOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIVER INJURY; MALE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RAT MODEL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; ANTIGENS, CD36; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIET, HIGH-FAT; DIETARY FATS; FATTY LIVER; GENE EXPRESSION; INSULIN RESISTANCE; LIPASE; LIPID METABOLISM; LIVER; MALE; OBESITY; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RNA, SMALL INTERFERING; TRITERPENES;

EID: 84897382346     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086724     Document Type: Article

References (53)

1. Angulo P, Lindor KD (2002) Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17 Suppl: S186-190. (Pubitemid 34539308)
2. Choudhury J, Sanyal AJ (2004) Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8: 575-594, ix. (Pubitemid 39141144)
3. James OF, Day CP (1998) Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501. (Pubitemid 28396672)
4. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845.
5. Rao MS, Reddy JK (2004) PPARalpha in the pathogenesis of fatty liver disease. Hepatology 40: 783-786. (Pubitemid 39288108)
6. Tailleux A, Wouters K, Staels B (2011) Roles of PPARs in NAFLD: Potential therapeutic targets. Biochim Biophys Acta.
7. Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116: 571-580. (Pubitemid 43326861)
8. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM (1997) Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 94: 2557-2562. (Pubitemid 27136914)
9. Teli MR, James OF, Burt AD, Bennett MK, Day CP (1995) The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22: 1714-1719.
10. Rafiq N, Younossi ZM (2008) Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 28: 427-433.
11. Jager S, Trojan H, Kopp T, Laszczyk MN, Scheffler A (2009) Pentacyclic triterpene distribution in various plants - rich sources for a new group of multipotent plant extracts. Molecules 14: 2016-2031.
12. Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49: 57-68.
13. Ikeda Y, Murakami A, Ohigashi H (2008) Ursolic acid: an anti- and proinflammatory triterpenoid. Mol Nutr Food Res 52: 26-42. (Pubitemid 351211800)
14. Li Y, Kang Z, Li S, Kong T, Liu X, et al. (2010) Ursolic acid stimulates lipolysis in primary-cultured rat adipocytes. Mol Nutr Food Res 54: 1609-1617.
15. Rao VS, de Melo CL, Queiroz MG, Lemos TL, Menezes DB, et al. (2011) Ursolic acid, a pentacyclic triterpene from Sambucus australis, prevents abdominal adiposity in mice fed a high-fat diet. J Med Food 14: 1375-1382.
16. Kunkel SD, Elmore CJ, Bongers KS, Ebert SM, Fox DK, et al. (2012) Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One 7: e39332.
17. Sundaresan A, Harini R, Pugalendi KV (2012) Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice. General physiology and biophysics 31: 323-333.
18. Jayaprakasam B, Olson LK, Schutzki RE, Tai MH, Nair MG (2006) Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J Agric Food Chem 54: 243-248. (Pubitemid 43119946)
19. Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, et al. (1990) Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85: 1349-1355. (Pubitemid 20360647)
20. Erickson SK (2009) Nonalcoholic fatty liver disease. J Lipid Res 50 Suppl: S412-416.
21. Liu Z, Li D, Zhao W, Zheng X, Wang J, et al. (2012) A potent lead induces apoptosis in pancreatic cancer cells. PLoS One 7: e37841.
22. Hu R, Zhou P, Peng YB, Xu X, Ma J, et al. (2012) 6-Shogaol induces apoptosis in human hepatocellular carcinoma cells and exhibits anti-tumor activity in vivo through endoplasmic reticulum stress. PLoS One 7: e39664.
23. Li S, Li Y, Ning H, Na L, Niu Y, et al. (2013) Calcium supplementation increases circulating cholesterol by reducing its catabolism via GPER and TRPC1-dependent pathway in estrogen deficient women. Int J Cardiol 168: 2548-2560.
24. Lu N, Li Y, Qin H, Zhang YL, Sun CH (2008) Gossypin up-regulates LDL receptor through activation of ERK pathway: a signaling mechanism for the hypocholesterolemic effect. J Agric Food Chem 56: 11526-11532.
25. Guo F, Huang C, Liao X, Wang Y, He Y, et al. (2011) Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol Nutr Food Res 55: 1809-1818.
26. Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American journal of physiology Gastrointestinal and liver physiology 290: G852-858.
27. Musso G, Gambino R, Cassader M (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in lipid research 48: 1-26.
28. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, et al. (2006) A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 169: 846-860. (Pubitemid 44411952)
29. Ferreira Dda S, Esperandim VR, Toldo MP, Saraiva J, Cunha WR, et al. (2010) Trypanocidal activity and acute toxicity assessment of triterpene acids. Parasitol Res 106: 985-989.
30. Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290: G852-858.
31. Jia Y, Bhuiyan MJ, Jun HJ, Lee JH, Hoang MH, et al. (2011) Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism. Bioorg Med Chem Lett 21: 5876-5880.
32. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, et al. (2003) Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 17: 259-272. (Pubitemid 36183149)
33. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, et al. (2005) Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 315: 58-68. (Pubitemid 41380498)
34. Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, et al. (2010) Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 53: 178-190.
35. Chen X, Lou G, Meng Z, Huang W (2011) TGR5: a novel target for weight maintenance and glucose metabolism. Exp Diabetes Res 2011: 853501.
36. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, et al. (2013) Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 288: 11761-11770.
37. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, et al. (2005) Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42: 362-371. (Pubitemid 41061089)
38. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL (2006) Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 285: 35-50.
39. Sun F, Xie ML, Xue J, Wang HB (2010) Osthol regulates hepatic PPAR alpha-mediated lipogenic gene expression in alcoholic fatty liver murine. Phytomedicine 17: 669-673.
40. Musso G, Gambino R, Cassader M (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26.
41. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152. (Pubitemid 39071617)
42. Le May C, Cauzac M, Diradourian C, Perdereau D, Girard J, et al. (2005) Fatty acids induce L-CPT I gene expression through a PPARalpha-independent mechanism in rat hepatoma cells. J Nutr 135: 2313-2319. (Pubitemid 41429583)
43. Fukao T, Lopaschuk GD, Mitchell GA (2004) Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids 70: 243-251. (Pubitemid 38200951)
44. Lewis JR, Mohanty SR (2010) Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55: 560-578.
45. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, et al. (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44: 1167-1174.
46. Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846.
47. Ip E, Farrell G, Hall P, Robertson G, Leclercq I (2004) Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39: 1286-1296. (Pubitemid 38569050)
48. Adams LA, Angulo P, Lindor KD (2005) Nonalcoholic fatty liver disease. CMAJ 172: 899-905. (Pubitemid 40543601)
49. Polyzos SA, Kountouras J, Zavos C (2009) Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 9: 299-314.
50. Tessari P, Coracina A, Cosma A, Tiengo A (2009) Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 19: 291-302.
51. Lonardo A, Carani C, Carulli N, Loria P (2006) 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 44: 1196-1207.
52. Hensley K, Kotake Y, Sang H, Pye QN, Wallis GL, et al. (2000) Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis 21: 983-989. (Pubitemid 30265144)
53. Laurent A, Nicco C, Tran Van Nhieu J, Borderie D, Chereau C, et al. (2004) Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 39: 1277-1285. (Pubitemid 38569049)